What happened
CRISPR/Cas9 in red blood cell-related diseases: breakthroughs in gene editing and therapy
SourceHong Kong Libo Information Consulting LimitedpublicationBiotech
CRISPR/Cas9 in red blood cell-related diseases: breakthroughs in gene editing and therapy
Publication signal: CRISPR/Cas9 in red blood cell-related diseases: breakthroughs in gene editing and therapy
Factual summary
Why it matters
Recent source-backed research output for AISci Stage A browsing.
SourceHong Kong Libo Information Consulting LimitedLimitations
AISci rank score does not assess scientific quality or citation impact.
SourceHong Kong Libo Information Consulting LimitedLinked output
CRISPR/Cas9 in red blood cell-related diseases: breakthroughs in gene editing and therapypaperPeople
No reviewed person relationship is attached to this event.
Organizations
No reviewed organization relationship is attached to this event.
Topics
Problems
No reviewed problem relationship is attached to this event.
Relationship evidence
Genomics and Gene Editing
Controlled AISci Stage A topic for Genomics and Gene Editing.
CRISPR/Cas9 in red blood cell-related diseases: breakthroughs in gene editing and therapy
CRISPR/Cas9 in red blood cell-related diseases: breakthroughs in gene editing and therapy
Timeline
- publicationCRISPR/Cas9 in red blood cell-related diseases: breakthroughs in gene editing and therapy